| Literature DB >> 21846326 |
Samer El-Kaissi1, Suphia Sherbeeni.
Abstract
While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase inhibitors, with the more recent addition of glucagon- like peptide-1 agonists, dipeptidyl peptidase-IV inhibitors and pramlintide. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. This review aims to provide an update on the current pharmacological management of type 2 diabetes mellitus, and to highlight the benefits and limitations of each treatment.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21846326 DOI: 10.2174/157339911797579160
Source DB: PubMed Journal: Curr Diabetes Rev ISSN: 1573-3998